SUNFLOWER PHARMACEUTICAL GROUP CO.,LTD |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 29.15 CNY | -1.15% |
|
-0.72% | +12.20% |
| 05-06 | China Grants Marketing Authorization to Sunflower Pharma's Electrolyte Powder for Constipation | MT |
| 04-26 | Sunflower Pharmaceutical Group Co.,Ltd Announces Profit Distribution Proposal for 2023 | CI |
ETFs positioned on Sunflower Pharmaceutical Group Co.,Ltd
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.23% | 4 M€ | -2.96% | ||
| 0.00% | 34 M€ | +3.87% | - |
SUNFLOWER PHARMACEUTICAL GROUP CO.,LTD is a China-based company principally engaged in the research, development, manufacture and sale of Chinese patent drugs, chemical drugs, biopharmaceuticals and health products. The Company provides drugs in six categories, including digestive medicine, pediatric medicine, gynecological medicine, rheumatoid bone medication, breathing cold medication and cardiovascular drugs. The Companyâs main products include Weikangling capsules, liver tablets, hyperactivity cough oral liquid for children use, pediatric Huatanzhike particles, Kangfu anti-inflammatory suppository and pediatric paracetamol particles, among others. The Company distributes its products in domestic market.
Sector
Pharmaceuticals
Calendar
2024-05-30
- Annual General Meeting
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| +12.20% | 2.36B | |
| +21.63% | 44.11B | |
| +23.03% | 22.71B | |
| +18.22% | 15.15B | |
| +12.66% | 13.56B | |
| +60.18% | 12.7B | |
| -10.02% | 6.84B | |
| -0.05% | 6.79B | |
| -8.87% | 5.73B | |
| +12.92% | 5.63B |
- Stock Market
- Equities
- 002737 Stock
- Funds and ETFs Sunflower Pharmaceutical Group Co.,Ltd
